Elekta AB (publ)
Elekta AB (publ) EKTAY Peers
See (EKTAY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EKTAY | $4.98 | -5.11% | 1.9B | 83.00 | $0.06 | +2.50% |
| SRTOY | $22.04 | N/A | 214.4B | 91.83 | $0.24 | +0.30% |
| ESLOY | $144.17 | +1.43% | 133B | 49.20 | $2.93 | +1.37% |
| ESLOF | $285.00 | +0.38% | 131.8B | 48.89 | $5.83 | +1.37% |
| MECNY | $88.63 | N/A | 107.8B | N/A | N/A | N/A |
| SOAGY | $47.70 | +1.04% | 74.8B | 149.06 | $0.32 | +0.16% |
| HOCPY | $117.91 | +1.52% | 40.4B | 29.40 | $4.01 | +0.44% |
| HOCPF | $111.89 | -2.70% | 38B | 27.09 | $4.13 | +0.97% |
| TRUMY | $18.19 | +1.00% | 27.1B | 33.07 | $0.55 | +0.33% |
| RSMDF | $22.00 | N/A | 26.8B | 24.72 | $0.89 | +0.84% |
Stock Comparison
EKTAY vs SRTOY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SRTOY has a market cap of 214.4B. Regarding current trading prices, EKTAY is priced at $4.98, while SRTOY trades at $22.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SRTOY's P/E ratio is 91.83. In terms of profitability, EKTAY's ROE is +0.10%, compared to SRTOY's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ESLOY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ESLOY has a market cap of 133B. Regarding current trading prices, EKTAY is priced at $4.98, while ESLOY trades at $144.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ESLOY's P/E ratio is 49.20. In terms of profitability, EKTAY's ROE is +0.10%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to ESLOY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ESLOF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ESLOF has a market cap of 131.8B. Regarding current trading prices, EKTAY is priced at $4.98, while ESLOF trades at $285.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ESLOF's P/E ratio is 48.89. In terms of profitability, EKTAY's ROE is +0.10%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs MECNY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, MECNY has a market cap of 107.8B. Regarding current trading prices, EKTAY is priced at $4.98, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas MECNY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SOAGY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SOAGY has a market cap of 74.8B. Regarding current trading prices, EKTAY is priced at $4.98, while SOAGY trades at $47.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SOAGY's P/E ratio is 149.06. In terms of profitability, EKTAY's ROE is +0.10%, compared to SOAGY's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SOAGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs HOCPY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, HOCPY has a market cap of 40.4B. Regarding current trading prices, EKTAY is priced at $4.98, while HOCPY trades at $117.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas HOCPY's P/E ratio is 29.40. In terms of profitability, EKTAY's ROE is +0.10%, compared to HOCPY's ROE of +0.15%. Regarding short-term risk, EKTAY is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs HOCPF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, HOCPF has a market cap of 38B. Regarding current trading prices, EKTAY is priced at $4.98, while HOCPF trades at $111.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas HOCPF's P/E ratio is 27.09. In terms of profitability, EKTAY's ROE is +0.10%, compared to HOCPF's ROE of +0.15%. Regarding short-term risk, EKTAY is less volatile compared to HOCPF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TRUMY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TRUMY has a market cap of 27.1B. Regarding current trading prices, EKTAY is priced at $4.98, while TRUMY trades at $18.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TRUMY's P/E ratio is 33.07. In terms of profitability, EKTAY's ROE is +0.10%, compared to TRUMY's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs RSMDF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, RSMDF has a market cap of 26.8B. Regarding current trading prices, EKTAY is priced at $4.98, while RSMDF trades at $22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas RSMDF's P/E ratio is 24.72. In terms of profitability, EKTAY's ROE is +0.10%, compared to RSMDF's ROE of +0.25%. Regarding short-term risk, EKTAY is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TRUMF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TRUMF has a market cap of 26.8B. Regarding current trading prices, EKTAY is priced at $4.98, while TRUMF trades at $18.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TRUMF's P/E ratio is 33.06. In terms of profitability, EKTAY's ROE is +0.10%, compared to TRUMF's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CLPBY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CLPBY has a market cap of 22.1B. Regarding current trading prices, EKTAY is priced at $4.98, while CLPBY trades at $9.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CLPBY's P/E ratio is 31.26. In terms of profitability, EKTAY's ROE is +0.10%, compared to CLPBY's ROE of +0.27%. Regarding short-term risk, EKTAY is more volatile compared to CLPBY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SDMHF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SDMHF has a market cap of 22B. Regarding current trading prices, EKTAY is priced at $4.98, while SDMHF trades at $225.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SDMHF's P/E ratio is 94.07. In terms of profitability, EKTAY's ROE is +0.10%, compared to SDMHF's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SAUHY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SAUHY has a market cap of 21.6B. Regarding current trading prices, EKTAY is priced at $4.98, while SAUHY trades at $13.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SAUHY's P/E ratio is 38.62. In terms of profitability, EKTAY's ROE is +0.10%, compared to SAUHY's ROE of +0.14%. Regarding short-term risk, EKTAY is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CLPBF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CLPBF has a market cap of 21.1B. Regarding current trading prices, EKTAY is priced at $4.98, while CLPBF trades at $93.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CLPBF's P/E ratio is 30.39. In terms of profitability, EKTAY's ROE is +0.10%, compared to CLPBF's ROE of +0.27%. Regarding short-term risk, EKTAY is less volatile compared to CLPBF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SAUHF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SAUHF has a market cap of 21B. Regarding current trading prices, EKTAY is priced at $4.98, while SAUHF trades at $131.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SAUHF's P/E ratio is 37.91. In terms of profitability, EKTAY's ROE is +0.10%, compared to SAUHF's ROE of +0.14%. Regarding short-term risk, EKTAY is less volatile compared to SAUHF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SARTF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SARTF has a market cap of 15.5B. Regarding current trading prices, EKTAY is priced at $4.98, while SARTF trades at $200.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SARTF's P/E ratio is 126.61. In terms of profitability, EKTAY's ROE is +0.10%, compared to SARTF's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to SARTF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs OCPNF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, OCPNF has a market cap of 15B. Regarding current trading prices, EKTAY is priced at $4.98, while OCPNF trades at $13.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas OCPNF's P/E ratio is 18.45. In terms of profitability, EKTAY's ROE is +0.10%, compared to OCPNF's ROE of +0.10%. Regarding short-term risk, EKTAY is more volatile compared to OCPNF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SUVPF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SUVPF has a market cap of 14.7B. Regarding current trading prices, EKTAY is priced at $4.98, while SUVPF trades at $259.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SUVPF's P/E ratio is 163.94. In terms of profitability, EKTAY's ROE is +0.10%, compared to SUVPF's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SUVPF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SSSGY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SSSGY has a market cap of 14.7B. Regarding current trading prices, EKTAY is priced at $4.98, while SSSGY trades at $42.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SSSGY's P/E ratio is 137.13. In terms of profitability, EKTAY's ROE is +0.10%, compared to SSSGY's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to SSSGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs FSPKF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, FSPKF has a market cap of 12.1B. Regarding current trading prices, EKTAY is priced at $4.98, while FSPKF trades at $20.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas FSPKF's P/E ratio is 53.08. In terms of profitability, EKTAY's ROE is +0.10%, compared to FSPKF's ROE of +0.10%. Regarding short-term risk, EKTAY is less volatile compared to FSPKF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SSMXY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SSMXY has a market cap of 10.4B. Regarding current trading prices, EKTAY is priced at $4.98, while SSMXY trades at $16.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SSMXY's P/E ratio is 27.68. In terms of profitability, EKTAY's ROE is +0.10%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, EKTAY is more volatile compared to SSMXY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SSMXF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SSMXF has a market cap of 9.2B. Regarding current trading prices, EKTAY is priced at $4.98, while SSMXF trades at $14.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SSMXF's P/E ratio is 24.55. In terms of profitability, EKTAY's ROE is +0.10%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CNVVY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CNVVY has a market cap of 8.3B. Regarding current trading prices, EKTAY is priced at $4.98, while CNVVY trades at $16.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CNVVY's P/E ratio is 43.73. In terms of profitability, EKTAY's ROE is +0.10%, compared to CNVVY's ROE of +0.16%. Regarding short-term risk, EKTAY is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CNVVF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CNVVF has a market cap of 7.3B. Regarding current trading prices, EKTAY is priced at $4.98, while CNVVF trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CNVVF's P/E ratio is 40.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to CNVVF's ROE of +0.16%. Regarding short-term risk, EKTAY is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CZMWF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CZMWF has a market cap of 6.1B. Regarding current trading prices, EKTAY is priced at $4.98, while CZMWF trades at $69.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CZMWF's P/E ratio is 34.49. In terms of profitability, EKTAY's ROE is +0.10%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to CZMWF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CZMWY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CZMWY has a market cap of 6.1B. Regarding current trading prices, EKTAY is priced at $4.98, while CZMWY trades at $69.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CZMWY's P/E ratio is 34.38. In terms of profitability, EKTAY's ROE is +0.10%, compared to CZMWY's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to CZMWY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs YPHDF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, YPHDF has a market cap of 5.7B. Regarding current trading prices, EKTAY is priced at $4.98, while YPHDF trades at $417.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas YPHDF's P/E ratio is 53.45. In terms of profitability, EKTAY's ROE is +0.10%, compared to YPHDF's ROE of +0.13%. Regarding short-term risk, EKTAY is less volatile compared to YPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs FLMNF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, FLMNF has a market cap of 5.4B. Regarding current trading prices, EKTAY is priced at $4.98, while FLMNF trades at $64.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas FLMNF's P/E ratio is 28.96. In terms of profitability, EKTAY's ROE is +0.10%, compared to FLMNF's ROE of +0.17%. Regarding short-term risk, EKTAY is more volatile compared to FLMNF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs FLMNY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, FLMNY has a market cap of 5.4B. Regarding current trading prices, EKTAY is priced at $4.98, while FLMNY trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas FLMNY's P/E ratio is 29.09. In terms of profitability, EKTAY's ROE is +0.10%, compared to FLMNY's ROE of +0.17%. Regarding short-term risk, EKTAY is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ADDLF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, EKTAY is priced at $4.98, while ADDLF trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, EKTAY's ROE is +0.10%, compared to ADDLF's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs AHICF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, AHICF has a market cap of 4.4B. Regarding current trading prices, EKTAY is priced at $4.98, while AHICF trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas AHICF's P/E ratio is 59.89. In terms of profitability, EKTAY's ROE is +0.10%, compared to AHICF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to AHICF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SHWGF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SHWGF has a market cap of 3.4B. Regarding current trading prices, EKTAY is priced at $4.98, while SHWGF trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SHWGF's P/E ratio is 12.67. In terms of profitability, EKTAY's ROE is +0.10%, compared to SHWGF's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TEVNF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TEVNF has a market cap of 3.2B. Regarding current trading prices, EKTAY is priced at $4.98, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TEVNF's P/E ratio is -0.21. In terms of profitability, EKTAY's ROE is +0.10%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, EKTAY is more volatile compared to TEVNF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ANSLY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ANSLY has a market cap of 2.9B. Regarding current trading prices, EKTAY is priced at $4.98, while ANSLY trades at $80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ANSLY's P/E ratio is 24.54. In terms of profitability, EKTAY's ROE is +0.10%, compared to ANSLY's ROE of +0.04%. Regarding short-term risk, EKTAY is less volatile compared to ANSLY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ANSLF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ANSLF has a market cap of 2.6B. Regarding current trading prices, EKTAY is priced at $4.98, while ANSLF trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ANSLF's P/E ratio is 22.22. In terms of profitability, EKTAY's ROE is +0.10%, compared to ANSLF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TCHBF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TCHBF has a market cap of 2.4B. Regarding current trading prices, EKTAY is priced at $4.98, while TCHBF trades at $191.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TCHBF's P/E ratio is 29.58. In terms of profitability, EKTAY's ROE is +0.10%, compared to TCHBF's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to TCHBF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TCGGY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, EKTAY is priced at $4.98, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TCGGY's P/E ratio is 27.91. In terms of profitability, EKTAY's ROE is +0.10%, compared to TCGGY's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs GRRMF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, GRRMF has a market cap of 1.9B. Regarding current trading prices, EKTAY is priced at $4.98, while GRRMF trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas GRRMF's P/E ratio is 21.36. In terms of profitability, EKTAY's ROE is +0.10%, compared to GRRMF's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to GRRMF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs EKTAF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, EKTAF has a market cap of 1.9B. Regarding current trading prices, EKTAY is priced at $4.98, while EKTAF trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas EKTAF's P/E ratio is 86.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to EKTAF's ROE of +0.10%. Regarding short-term risk, EKTAY is less volatile compared to EKTAF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs BOEUF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, BOEUF has a market cap of 1.8B. Regarding current trading prices, EKTAY is priced at $4.98, while BOEUF trades at $27.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas BOEUF's P/E ratio is 146.34. In terms of profitability, EKTAY's ROE is +0.10%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, EKTAY is more volatile compared to BOEUF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TGLVY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TGLVY has a market cap of 1.6B. Regarding current trading prices, EKTAY is priced at $4.98, while TGLVY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TGLVY's P/E ratio is 79.97. In terms of profitability, EKTAY's ROE is +0.10%, compared to TGLVY's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to TGLVY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs NPRRF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, EKTAY is priced at $4.98, while NPRRF trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas NPRRF's P/E ratio is 44.74. In terms of profitability, EKTAY's ROE is +0.10%, compared to NPRRF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to NPRRF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TDVXF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TDVXF has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $4.98, while TDVXF trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TDVXF's P/E ratio is 71.34. In terms of profitability, EKTAY's ROE is +0.10%, compared to TDVXF's ROE of +0.39%. Regarding short-term risk, EKTAY is more volatile compared to TDVXF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs BITGF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $4.98, while BITGF trades at $14.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas BITGF's P/E ratio is 45.06. In terms of profitability, EKTAY's ROE is +0.10%, compared to BITGF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to BITGF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs PBHDF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, PBHDF has a market cap of 1.1B. Regarding current trading prices, EKTAY is priced at $4.98, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, EKTAY's ROE is +0.10%, compared to PBHDF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs KSRBF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, KSRBF has a market cap of 866.4M. Regarding current trading prices, EKTAY is priced at $4.98, while KSRBF trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas KSRBF's P/E ratio is 4.87. In terms of profitability, EKTAY's ROE is +0.10%, compared to KSRBF's ROE of +0.03%. Regarding short-term risk, EKTAY is less volatile compared to KSRBF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs NNCSF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, NNCSF has a market cap of 804.5M. Regarding current trading prices, EKTAY is priced at $4.98, while NNCSF trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas NNCSF's P/E ratio is 88.33. In terms of profitability, EKTAY's ROE is +0.10%, compared to NNCSF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to NNCSF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SHWGY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SHWGY has a market cap of 788.6M. Regarding current trading prices, EKTAY is priced at $4.98, while SHWGY trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SHWGY's P/E ratio is 11.16. In terms of profitability, EKTAY's ROE is +0.10%, compared to SHWGY's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to SHWGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SPMXF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SPMXF has a market cap of 550.3M. Regarding current trading prices, EKTAY is priced at $4.98, while SPMXF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SPMXF's P/E ratio is -18.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to SPMXF's ROE of -0.05%. Regarding short-term risk, EKTAY is more volatile compared to SPMXF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs JNDOF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, JNDOF has a market cap of 531M. Regarding current trading prices, EKTAY is priced at $4.98, while JNDOF trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, EKTAY's ROE is +0.10%, compared to JNDOF's ROE of +0.20%. Regarding short-term risk, EKTAY is more volatile compared to JNDOF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs HGYMF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, HGYMF has a market cap of 524.8M. Regarding current trading prices, EKTAY is priced at $4.98, while HGYMF trades at $24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas HGYMF's P/E ratio is 33.81. In terms of profitability, EKTAY's ROE is +0.10%, compared to HGYMF's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to HGYMF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SAFLY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SAFLY has a market cap of 449.6M. Regarding current trading prices, EKTAY is priced at $4.98, while SAFLY trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SAFLY's P/E ratio is 223.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to SAFLY's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to SAFLY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CLHLF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, EKTAY is priced at $4.98, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, EKTAY's ROE is +0.10%, compared to CLHLF's ROE of +0.12%. Regarding short-term risk, EKTAY is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SAFLF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SAFLF has a market cap of 306.5M. Regarding current trading prices, EKTAY is priced at $4.98, while SAFLF trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SAFLF's P/E ratio is 12.67. In terms of profitability, EKTAY's ROE is +0.10%, compared to SAFLF's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to SAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs GUERF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, EKTAY is priced at $4.98, while GUERF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas GUERF's P/E ratio is 8.19. In terms of profitability, EKTAY's ROE is +0.10%, compared to GUERF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to GUERF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TSNLF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TSNLF has a market cap of 252.4M. Regarding current trading prices, EKTAY is priced at $4.98, while TSNLF trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TSNLF's P/E ratio is 33.06. In terms of profitability, EKTAY's ROE is +0.10%, compared to TSNLF's ROE of +0.21%. Regarding short-term risk, EKTAY is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs OPSSF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, EKTAY is priced at $4.98, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, EKTAY's ROE is +0.10%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, EKTAY is more volatile compared to OPSSF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs MCDA Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, MCDA has a market cap of 212M. Regarding current trading prices, EKTAY is priced at $4.98, while MCDA trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas MCDA's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to MCDA's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to MCDA. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs EEOIF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, EKTAY is priced at $4.98, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, EKTAY's ROE is +0.10%, compared to EEOIF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs UEEC Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, UEEC has a market cap of 36M. Regarding current trading prices, EKTAY is priced at $4.98, while UEEC trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas UEEC's P/E ratio is -14.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to UEEC's ROE of +1.31%. Regarding short-term risk, EKTAY is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs TUTH Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, TUTH has a market cap of 15.2M. Regarding current trading prices, EKTAY is priced at $4.98, while TUTH trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas TUTH's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to TUTH's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to TUTH. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs OTCFF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, OTCFF has a market cap of 11.9M. Regarding current trading prices, EKTAY is priced at $4.98, while OTCFF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas OTCFF's P/E ratio is -13.84. In terms of profitability, EKTAY's ROE is +0.10%, compared to OTCFF's ROE of +18.74%. Regarding short-term risk, EKTAY is less volatile compared to OTCFF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs YBGJ Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, YBGJ has a market cap of 10.2M. Regarding current trading prices, EKTAY is priced at $4.98, while YBGJ trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas YBGJ's P/E ratio is -4.25. In terms of profitability, EKTAY's ROE is +0.10%, compared to YBGJ's ROE of +3.46%. Regarding short-term risk, EKTAY is more volatile compared to YBGJ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs OJSY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, OJSY has a market cap of 9.1M. Regarding current trading prices, EKTAY is priced at $4.98, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas OJSY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to OJSY's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to OJSY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs GVDI Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, GVDI has a market cap of 8.1M. Regarding current trading prices, EKTAY is priced at $4.98, while GVDI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas GVDI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to GVDI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs IMTH Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, IMTH has a market cap of 8.1M. Regarding current trading prices, EKTAY is priced at $4.98, while IMTH trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas IMTH's P/E ratio is -0.44. In terms of profitability, EKTAY's ROE is +0.10%, compared to IMTH's ROE of +2.29%. Regarding short-term risk, EKTAY is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs BLMHF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, EKTAY is priced at $4.98, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, EKTAY's ROE is +0.10%, compared to BLMHF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs PXMVF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, EKTAY is priced at $4.98, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, EKTAY's ROE is +0.10%, compared to PXMVF's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CBSC Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, EKTAY is priced at $4.98, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CBSC's P/E ratio is -4.02. In terms of profitability, EKTAY's ROE is +0.10%, compared to CBSC's ROE of +1.52%. Regarding short-term risk, EKTAY is more volatile compared to CBSC. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs RSCF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, RSCF has a market cap of 4.4M. Regarding current trading prices, EKTAY is priced at $4.98, while RSCF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas RSCF's P/E ratio is -5.19. In terms of profitability, EKTAY's ROE is +0.10%, compared to RSCF's ROE of +0.08%. Regarding short-term risk, EKTAY is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ECIA Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ECIA has a market cap of 4.4M. Regarding current trading prices, EKTAY is priced at $4.98, while ECIA trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ECIA's P/E ratio is -9.25. In terms of profitability, EKTAY's ROE is +0.10%, compared to ECIA's ROE of -0.33%. Regarding short-term risk, EKTAY is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs NSTGQ Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, EKTAY is priced at $4.98, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs PDMI Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, EKTAY is priced at $4.98, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas PDMI's P/E ratio is -0.01. In terms of profitability, EKTAY's ROE is +0.10%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, EKTAY is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs REMI Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, REMI has a market cap of 200K. Regarding current trading prices, EKTAY is priced at $4.98, while REMI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas REMI's P/E ratio is -1.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to REMI's ROE of -0.08%. Regarding short-term risk, EKTAY is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs WHSI Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, EKTAY is priced at $4.98, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas WHSI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, EKTAY is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs QTXB Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, EKTAY is priced at $4.98, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas QTXB's P/E ratio is -0.05. In terms of profitability, EKTAY's ROE is +0.10%, compared to QTXB's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs CEOS Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, CEOS has a market cap of 106.8K. Regarding current trading prices, EKTAY is priced at $4.98, while CEOS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas CEOS's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to CEOS's ROE of +1.18%. Regarding short-term risk, EKTAY is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SVSO Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SVSO has a market cap of 63.8K. Regarding current trading prices, EKTAY is priced at $4.98, while SVSO trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SVSO's P/E ratio is -0.17. In terms of profitability, EKTAY's ROE is +0.10%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, EKTAY is less volatile compared to SVSO. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs LANZ Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, LANZ has a market cap of 27.7K. Regarding current trading prices, EKTAY is priced at $4.98, while LANZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas LANZ's P/E ratio is 1.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, EKTAY is more volatile compared to LANZ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs GMVDF Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, EKTAY is priced at $4.98, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas GMVDF's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, EKTAY is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs VSMD Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, VSMD has a market cap of 22.4K. Regarding current trading prices, EKTAY is priced at $4.98, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas VSMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, EKTAY is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ASFX Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ASFX has a market cap of 17.5K. Regarding current trading prices, EKTAY is priced at $4.98, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ASFX's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to ASFX. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs MDIT Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, MDIT has a market cap of 17.2K. Regarding current trading prices, EKTAY is priced at $4.98, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas MDIT's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, EKTAY is less volatile compared to MDIT. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs INND Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, INND has a market cap of 17.2K. Regarding current trading prices, EKTAY is priced at $4.98, while INND trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas INND's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to INND's ROE of +0.32%. Regarding short-term risk, EKTAY is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs LFPI Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, LFPI has a market cap of 10.2K. Regarding current trading prices, EKTAY is priced at $4.98, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas LFPI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, EKTAY is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SECI Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SECI has a market cap of 9.2K. Regarding current trading prices, EKTAY is priced at $4.98, while SECI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SECI's P/E ratio is -0.18. In terms of profitability, EKTAY's ROE is +0.10%, compared to SECI's ROE of -0.00%. Regarding short-term risk, EKTAY is less volatile compared to SECI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs DGEN Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, EKTAY is priced at $4.98, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas DGEN's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs BLFE Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, BLFE has a market cap of 1.6K. Regarding current trading prices, EKTAY is priced at $4.98, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas BLFE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to BLFE's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to BLFE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SEYE Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, EKTAY is priced at $4.98, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SEYE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to SEYE's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs BGMD Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, EKTAY is priced at $4.98, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas BGMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to BGMD's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to BGMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs ADLI Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, EKTAY is priced at $4.98, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas ADLI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, EKTAY is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs HRAL Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, HRAL has a market cap of 446. Regarding current trading prices, EKTAY is priced at $4.98, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas HRAL's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to HRAL's ROE of +0.13%. Regarding short-term risk, EKTAY is less volatile compared to HRAL. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs SDCCQ Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, SDCCQ has a market cap of 403. Regarding current trading prices, EKTAY is priced at $4.98, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, EKTAY is more volatile compared to SDCCQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs MICRD Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, EKTAY is priced at $4.98, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas MICRD's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, EKTAY is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs RGBOQ Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, EKTAY is priced at $4.98, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs VTEQ Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, EKTAY is priced at $4.98, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is +0.10%, compared to VTEQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.
EKTAY vs OCPNY Comparison
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 1.9B. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, EKTAY is priced at $4.98, while OCPNY trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of 83.00, whereas OCPNY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is +0.10%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, EKTAY is more volatile compared to OCPNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.